Survivors of allogeneic hematopoietic stem cell transplantation (HSCT) are at a life-long increased risk of secondary nonhematologic malignancies. In 615 adult Chinese allogeneic HSCT patients, nine developed nonhematologic malignancies. The 5-year cumulative incidence was 6.1%, 4.5 times the background cancer incidence. Early-onset (within first 6 months) and late-onset (43 years) subtypes were observed. Secondary cancers included hepatocellular carcinoma, oral and esophageal squamous cell tumors and lung adenocarcinoma in a female nonsmoker. The spectrum reflected local cancer epidemiology, which was different from Western populations. The pathogenesis might be related to acceleration of pre-existing cancers (early-onset type), or prolonged immunosuppression (late-onset type). DNA chimerism studies showed that all tumors were recipient-derived. In the plasma, DNA in all cases was apparently donor-derived, although aberrantly methylated p15 was detectable in a patient with a p15-methylated secondary cancer, implying that minute quantities of tumor (and therefore recipient) derived DNA might be present. Recipients of hematopoietic stem cell transplantation (HSCT) have an increased risk of second malignancies, owing to repeated exposure to high-dose chemotherapy and radiotherapy pre-HSCT, and prolonged immunosuppression post-HSCT. In patients receiving autologous HSCT, owing to the engraftment of HSC that had previously been exposed to chemotherapy and radiotherapy, the commonest second malignancy is therapy-related leukemia/ myelodysplasia (t-AML/MDS).
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Recipients of hematopoietic stem cell transplantation (HSCT) have an increased risk of second malignancies, owing to repeated exposure to high-dose chemotherapy and radiotherapy pre-HSCT, and prolonged immunosuppression post-HSCT. In patients receiving autologous HSCT, owing to the engraftment of HSC that had previously been exposed to chemotherapy and radiotherapy, the commonest second malignancy is therapy-related leukemia/ myelodysplasia (t-AML/MDS). 1, 2 The other common malignancy is post transplantation lymphoproliferative diseases (PTLD), arising as a result of immunosuppression post-HSCT, which typically occurs after allogeneic HSCT, although occasional cases have also been reported after autologous HSCT. 1, 2 Prolonged follow-up of a large number of allogeneic HSCT recipients has also shown increased risks of other nonhematologic malignancies. 2 Owing to peculiar etiologic factors, the incidence and spectrum of these cancers are different from de novo malignancies, and may also vary in different ethnic groups. Skin cancers and melanomas are common, followed by cancers of the breast, lung, brain and thyroid gland. These patterns probably reflect the prevalent cancer epidemiology in the populations studied.
To date, the pattern of second malignancies in the Chinese population has not been reported. We surveyed the incidence of solid tumors in consecutive cases of adult Chinese HSCT recipients over a 12-year period. Furthermore, we evaluated the possible use of molecular markers in the peripheral blood for the detection of these malignancies, as the practice of regular molecular monitoring in HSCT recipients may allow early molecular detection of tumors in individuals at risk.
Material and methods

Patients
Between 1990 and 2003, 615 consecutive unselected adult patients underwent allogeneic HSCT and were followed up at Queen Mary Hospital, Hong Kong. There were 317 males and 224 females, at a median age of 35.5 (18-65) years. The conditioning regimen included total-body irradiation in 260 cases. Prophylaxis against graft versus host disease (GVHD) comprised cyclosporine and methotrexate in all the cases. Significant acute GVHD (grade III or above) and chronic GVHD occurred in 133 and 167 cases, respectively. Death due to therapy-related mortality and disease relapses occurred in 98 and 146 cases, respectively. In the 371 survivors, at a median follow-up of 41 (1-164) months, four cases of t-MDS/AML, five cases of PTLD, 3 and nine cases of nonhematologic malignancies were identified. During the same period, only one case of solid tumor was diagnosed among 171 cases of autologous HSCT. 4 
Statistical analysis
The cumulative incidence of nonhematologic malignancies was calculated by censoring cases on the day of cancer diagnosis or last follow-up. Deaths due to noncancerous causes were entered as a competing risk. The risks of nonhematologic malignancies were assessed by the Cox model. Standardized cancer incidence ratios (SIRs) were used to compare the cancer incidence of the HSCT patients with that of the general population. Cancer incidence rates were calculated from sex-matched incidence rates from the Hong Kong Cancer Registry.
5 Two-sided t-test and 95% confidence intervals (CI) for the SIRs were calculated by comparing the observed number of second malignancies with the calculated expected number of cancers. 15 
Molecular tests
DNA was extracted from paraffin-embedded tumor tissues, marrow aspirate, peripheral blood and cell-free plasma by commercial kits (Qiagen, Valencia, CA, USA) as described. 6 Analysis of DNA chimerism was performed by a semiquantitative analysis of polymorphic microsatellite markers, which had a sensitivity of about 5% in differentiating two polymorphic loci, as previously reported. 6 Methylation-specific PCR (MSP) for the p15 gene, with a sensitivity of 10 À3 , was performed as previously described. 6 For selected cases, molecular tests of possible minimal residual disease of the original hematologic malignancy were performed (for BCR/ABL and AML1/ ETO fusion genes) as appropriate, with a sensitivity of 10 À4 -10
À6
.
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Results
Patients
Six men and three women developed nonhematologic malignancies, at a median age of 48 (38-56) years (Table 1 ). All patients were nonsmokers. Cancers occurred at 2-107 months post-HSCT, and could be divided into early (2-6 months) and late (56-105 months) onset groups.
Early-onset secondary cancers
Three patients developed advanced cancers within 6 months. Case 1 had blastic relapse of chronic myeloid leukemia (CML) and was treated with imatinib mesylate. At the same time, grade IV GVHD persisted and required intensive immunosuppression. At 1 month post-HSCT, bronchogenic adenocarcinoma became evident as pleural effusion, and death rapidly ensued. Case 2 underwent a nonmyeloablative HSCT for multiple myeloma. At 2 months post-HSCT, partial gastrectomy was performed for gastrointestinal bleeding, during which gastric adenocarcinoma was diagnosed. Case 3 had severe aplastic anemia and failed to engraft. Refractory ascites due to ovarian carcinoma developed 4 months afterwards and led to death. 
Late-onset secondary cancers
Six patients developed late-onset cancers. There were two cases of hepatocellular carcinoma (HCC). Case 5 was negative for hepatitis B and C viruses (HBV, HCV), but had received extensive radiotherapy for ankylosing spondylitis. 7 He developed massive HCC and died from liver failure. Case 7 was a chronic HBV carrier, and had a solitary 4-cm HCC identified during routine ultrasonographic screening. Partial hepatectomy was successfully performed. Three patients developed cancers in the upper aerodigestive tract (tongue, n ¼ 2; esophagus, n ¼ 1). The clinical details of two of them have been reported elsewhere. 8 None of these patients had associated risk factors, including chronic smoking and alcohol use. Case 9 developed breast cancer nearly 10 years post-HSCT.
Statistical analysis
Nonhematologic malignancies occurred more frequently than the expected background of 2.45 cases (relative risk: 4.5, 95% confidence interval, CI: 1.1-21.1, P ¼ 0.034). The cumulative incidence of cancers at 5 years was 6.170.027%, which was comparable with that observed for the autologous HSCT group (3.1%) (P ¼ 0.54). Reported risk factors for the development of nonhematologic malignancies, including previous irradiation (totalbody irradiation, TBI, n ¼ 4; dose-limiting radiotherapy to the axial skeleton, n ¼ 2), and chronic graft-versus-host disease (GVHD) requiring multiple immunosuppressants (n ¼ 5) were examined by univariate analysis. They were not significantly associated with secondary malignancies.
Laboratory monitoring
DNA material was not available for case 3, while chimerism could not be analyzed after syngeneic HSCT in case 9. In six informative patients (cases 2, 4-8.) with suitable clinical specimens, analysis of marrow and plasma DNA showed full donor chimerism (Table 2) . In case 1, recipient chimerism was predominant after relapse of chronic myeloid leukemia in blastic crisis. Donor chimerism resurged after treatment with imatinib mesylate, which resulted in re-engraftment of donor hematopoietic cells (Figure 1 ). Her bronchogenic carcinoma, however, was entirely recipient in origin. Aberrant p15 methylation occurred in the tumor in four cases (cases 1, 4, 5 and 6). In case 6, methylated p15 was also detectable in the plasma. As the primary disease (acute myeloid leukemia with AML1/ETO) of case 6 was in clinical and molecular remission, the plasma methylated p15 was most likely derived from the secondary cancer.
Discussion
The incidence and spectrum of nonhematologic malignancies after allogeneic HSCT have been reported mainly in Western series. The commonest tumors included squamous cell carcinomas of the skin, uterine cervix and oral cavity, melanoma and HCC in hepatitis C virus carriers. 9, 10 The reported actuarial long-term incidence rates ranged from 3.8 to 11%, 9-14 with a relative risk of 1.3-5.0 times that of the background population. [9] [10] [11] [12] [13] [14] (Table 3 ). The variations may be due to reporting bias from registry data, or differences in the age, background cancer incidences and screening policies of the populations concerned. It is interesting to note that the predominant cancers reported were skin cancer, melanomas, and cancers of the breast and lungs, which mirrored the pattern seen in the corresponding normal population. However, the incidences of brain and thyroid cancers were particularly high in series involving large number of pediatric and adolescent HSCT, which might be related to peculiar developmental problems. These features, however, were not seen in our cohort. 13, 14 In this study, we described the first Chinese series of nonhematologic malignancies after allogeneic HSCT. The pattern represented the common cancers observed in Chinese patients, including HCC in hepatitis B virus carriers, gastric, oral and esophageal carcinoma, and bronchogenic adenocarcinoma in female nonsmokers. 5 On the other hand, skin cancers and melanomas were not observed, consistent with the very low background incidence of these malignancies in Chinese. The pattern of nonhematologic malignancies post-HSCT in Chinese patients thus reflects the spectrum of common cancers in this population, and is consequently dissimilar from Western patients. Physicians taking care of Chinese patients should be aware of these differences.
Previous studies have shown that TBI 12, 15 and chronic GVHD 11 were risk factors for post-HSCT secondary cancers. In this study, with our small number of patients, we were not able to show this relationship. However, in our early-onset group with cancers arising within weeks to months of HSCT, TBI and GVHD were in any case unlikely to be important etiologic factors. It is possible that intense immunosuppression during conditioning might hasten the rapid progression of pre-existing malignant cells. 16 We further investigated the feasibility of using plasma DNA for the monitoring and detection of secondary cancers post-HSCT. The development of solid tumors is often accompanied by the release of tumor DNA into the plasma, leading to an increase in the absolute amount of circulating DNA. 17, 18 Methods employed in the detection of tumor-derived DNA include analysis of loss of heterozygosity 19 or for the presence of aberrant gene methylation. 20 However, in post-HSCT patients, a unique feature is that plasma DNA is donor in origin, whereas any putative tumor-derived circulating DNA is recipient in origin. This might provide a means for the differential determination of tumor-derived DNA. Using a semiquantitative PCR for DNA chimerism, however, we were not able to detect any recipient-derived plasma DNA in any of our patients with secondary malignancies. In contrast, with a more sensitive MSP technique, we were able to detect in a patient with a p15-methylated secondary tumor the presence of aberrantly methylated p15, which was therefore of putative recipient origin. Thus, the quantification of recipient-derived plasma DNA based on polymorphic loci might not provide enough Table 3 Incidence and risks of nonhematologic cancers after hematopoietic stem cell transplantation (HSCT) 
